Background: We evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP) in a 'real-life' setting of patients with AML receiving intensive consolidation therapy.
Results: Of 2588 patients, 56 (2.2%) developed IA [43 probable (1.7%) and 13 proven (0.5%)]. IA was diagnosed in 34 of 1137 (2.9%) patients receiving no AP and in 22 of 1451 (1.5%) who were given AP (P"0.01). Numberneeded-to-treat calculation indicates that, on average, 71 patients should have received AP (instead of no AP) for one additional patient to not have IA. Initial antifungal therapy was 'pre-emptive' in 36 (64%) patients and 'targeted' in 20 (36%) patients. A good response to first-line therapy was observed in 26 (46%) patients, mainly those who received AP [16 of 22 (73%) versus 10 of 34 (29%); P"0.001]. The overall mortality rate and the mortality rate attributable to IA by day 120 were 16% and 9%, respectively. In multivariate analysis, age 60 years (OR"12.46, 95% CI"1.13-136.73; P"0.03) and high-dose cytarabine treatment (OR"10.56, 95% CI"1.95-116.74; P"0.04) independently affected outcome. 
Introduction
Over recent years, considerable progress has been made in understanding AML pathogenesis and in the development of diagnostic assays and novel therapies. 1 Despite these advances 2 the outcome of AML remains poor due to features intrinsic to the disease or due to complications, such as infections, occurring as a side effect of the intensive regimens that are adopted. Among infections, invasive aspergillosis (IA) is one of the most frequent conditions in AML. IA can be life-threatening and very difficult to eradicate, so that the normal chemotherapeutic course can be substantially altered, compromising the attempt of a successful cure of underlying AML.
Accordingly, efforts have been made to implement strategies of antifungal prophylaxis (AP) to prevent IA. Cornely et al. 3 demonstrated that a prophylaxis with posaconazole, given during neutropenia following AML induction therapy, was superior to a prophylaxis with itraconazole or fluconazole in preventing proven/ probable invasive fungal infection and was associated with relative reduction of mortality. Several retrospective studies confirmed these results [4] [5] [6] and current international guidelines recommend prophylaxis with posaconazole during the induction phase, based on the high level of evidence. [7] [8] [9] [10] However, investigators focused on the role of AP given during the induction chemotherapy of AML, with few studies exploring whether there was a role for AP also in patients receiving consolidation chemotherapy. The reason for this lack of interest is that the incidence of IA during consolidation therapy is considered a rare event, [11] [12] [13] [14] [15] [16] although such a perception does not rely on robust evidence. As a matter of fact, the epidemiology of IA in the induction phase has been extensively investigated, whereas only limited data are available with regards to the incidence and characteristics of IA occurring during consolidation. Actually, considering the bone marrow suppression following consolidation chemotherapy, patients are at risk of developing IA even in this phase of the therapeutic programme. Similarly to induction, a diagnosis of IA during consolidation does have a potential impact on prognosis, since it may cause a delay in the subsequent therapeutic programme and prolong hospitalization, eventually increasing the overall costs of disease. Furthermore, while, among the different haematological centres, there is a consensus about the adopted strategies of AP during induction, the prophylaxis during consolidation varies consistently.
Based on these observations, we analysed, retrospectively, a large 'real-life' series of patients with AML with the aim to: (i) evaluate the current rate of proven and probable IA in patients with AML submitted to intensive consolidation therapy; (ii) identify risk factors that, following consolidation, are associated with IA; and (iii) assess the role of AP as delivered either in induction or consolidation in preventing IA from occurring after consolidation therapy. 17 Cases were documented using a case report form. Variables included the following data: age, gender, AML onset, genetic/cytogenetic risk factors, 1 duration of neutropenia (,10 versus 10 days), comorbidity conditions (diabetes, COPD, renal/hepatic failure), mucosal damage, diarrhoea, steroid administration and details of chemotherapeutic regimens. The clinical characteristics of patients with IA were compared with those of a control group, including 102 individuals matched for age and treatment, selected in the same period and in the same centres. Additional data collected were: AP, infections, site of infection, diagnostic microbiology, (direct microscopy, cultures, and galactomannan assay in serum or in bronchoalveolar lavage), imaging and histology, date of antifungal therapy initiation and whether this was 'pre-emptive' or 'targeted', and date of death. 'Preemptive' treatment was initiated in patients with persistent fever and imaging suspected of having IA. In patients with compatible radiological signs and microbiological tests allowing identification of the pathogen and in those with histopathological evidence of an aspergillosis, 'targeted' therapy was initiated. The assessment of response to therapy relied on clinical evaluation, quantitative laboratory tests and to a lesser extent imaging studies. 18, 19 Death was defined as early (,30 days) or late (.30 days) after the diagnosis of IA. Mortality was regarded as attributable to IA if the patient died within 120 days since consolidation initiation and had microbiological, histological or clinical evidence of IA and when any alternative cause had been excluded.
Methods

Statistical analysis
Continuous variables were compared with Student's t-test (for normally distributed variables) or the Mann-Whitney U-test (for non-normally distributed variables). Categorical variables were evaluated with the v 2 or twotailed Fisher's exact test. ORs and 95% CIs were calculated for all associations that emerged. Results are expressed as mean + SD or median (range) (continuous variables) or as percentages of the group from which they were derived (categorical variables). Two-tailed tests were used to determine statistical significance; P , 0.05 was considered significant. Multivariate analysis was used to identify independent risk factors for mortality. For this analysis, we used logistic regression, and variables found to be significant in univariate testing were incorporated with a stepwise approach. The number needed to treat to achieve one additional patient free from IA was calculated as the reciprocal of the rate difference between AP and no prophylaxis.
Ethical considerations
Approval of the local institutional review board and ethics committee was obtained at all participating sites.
Results
Of 2588 patients in complete remission after induction therapy and therefore submitted to consolidation, 56 (2.2%) developed IA. Cases of IA probable predominated over histologically proven cases [43 (1.7%) versus 13 (0.5%)]. Characteristics of the 56 Aspergillosis in AML consolidation JAC patients with IA are summarized in Table 1 . As consolidation therapy, 14 (25%) patients received standard-dose cytarabine (100 mg/m 2 , days 1-5, continuous infusion), 21 (37.5%) patients received intermediate-dose cytarabine (500 mg/m 2 every 12 h, days 1-6) and 21 patients received high-dose cytarabine (2 g/m 2 /day, days 1-5 or 1, 3, 5 and 7). Thirty-four patients were also given anthracycline together with cytarabine. The lung was the most frequently involved site (50 of 56; 89%); 8 patients (14%) had a disseminated IA with at least three sites involved. Four patients also presented a history of IA during the induction phase. No significant differences were observed between patients who developed proven IA and those with probable IA (see Table 1 ).
Risk factors
To identify potential risk factors associated with the development of proven/probable IA during/after consolidation therapy, we compared the clinical characteristics of patients diagnosed with IA with those of the control group. In univariate analysis none of the variables analysed were significantly associated with the risk of IA during consolidation (see Table 2 ).
Prophylaxis during induction and consolidation
Most patients (2199, 85%) received prophylactic posaconazole during the previous induction phase while the remaining 389 (15%) received other antifungal agents. There were no significant differences in the incidence of IA after consolidation based on the type of AP delivered in the induction (posaconazole versus other agents). On the other hand, delivering AP in consolidation was associated with a significant benefit. In fact, the diagnosis of IA was made in 34 of 1137 (2.9%) patients who did not receive AP and in 22 of 1451 who did receive it (1.5%) (P , 0.01). The number needed to treat to achieve one additional patient who will benefit from the AP was 71. In other words, on average, 71 patients would have to receive AP (instead of no AP) for one additional patient to not have IA. Table 3 summarizes the distribution of patients in the different consolidation-course AP groups.
Furthermore, AP was able to reduce the failure of the first antifungal therapy. In fact, the success of antifungal therapy was observed in 16 of 22 (73%) patients who received AP and in 10 of 34 (29%) who did not receive AP (P"0.001).
Treatment and response to antifungal therapy 'Pre-emptive' antifungal therapy was started in 36 patients (64%), mainly with liposomal amphotericin B [22 (61%); P , 0.0005], while the remaining 20 (37%) received a 'targeted' approach. Thirteen patients switched from liposomal amphotericin B to voriconazole, so that the most frequently targeted antifungal therapy was voriconazole (28 of 56, 50%). Combined therapy was given as first-line targeted therapy in four patients (7%). The most frequent combination was liposomal amphotericin B plus voriconazole. Efficacy of treatment was assessed by the rate of success of the first-line therapy. Of 56 patients, 26 (46%) had a good response. However, when considering the drugs most frequently used in first-line therapy, no significant differences emerged in univariate analysis with regard to outcome ( Table 4) .
Outcome
The early mortality rate was 9% (5 of 56) while the late mortality rate was 16% (9 of 56). No significant inter-centre differences were observed. Death due to IA or occurring in the presence of IA (mortality attributable to IA) occurred in 7% of patients (4 of 56) by day 30 and in 9% (5 of 56) by day 120. Other causes of mortality were bacterial infections and AML progression (the latter particularly for late deaths). Univariate analysis showed that the parameters that influenced outcome were the duration of neutropenia 10 days, treatment with high-dose cytarabine or age 60 years (see Table 4 ). Multivariate analysis confirmed that age 60 years (OR"12.46, 95% CI"1.13-136.73; P"0.03) and high-dose cytarabine (OR"10.56, 95% CI"1.95-116.74; P"0.04) were factors that independently affected outcome. Taking into account the overall population receiving the consolidation course, the overall mortality rate and the mortality rate attributable to IA on day 120 were 0.34% and 0.19%, respectively.
Discussion
This retrospective study focuses on the incidence of proven/probable IA and the role of AP in a multicentre large 'real-life' series of consecutive adult and paediatric patients with AML submitted to consolidation chemotherapy. Overall, the incidence of IA was 2.2%: our observation is comparable to that reported in the past decade, in which the frequency of invasive fungal infection ranged from 2% 16, 20 to 3%. 13 Thus, although significant progress has been made in the cure of patients with AML, the incidence of IA after consolidation is stable over time.
Owing to the inhalation of dormant spores from the environment, the lung is the most frequent site of IA development. 13 The Aspergillus spores break quiescence and grow in the human lung, exploiting the neutropenia and mucosal damage. 18 The pivotal role of neutrophils in the host defence against Aspergillus infections is well known, 21, 22 particularly when mucosal barriers have been disrupted. As reported in other studies [23] [24] [25] the use of high-dose cytarabine-based regimens was not associated with a higher incidence of IA. However, in our experience, treatment with high-dose cytarabine had a significant impact on the mortality rate attributable to IA, due to the profound neutropenia and extensive gastrointestinal mucosal damage associated with the administration of this high-dose regimen. In addition, the profound neutropenia occurring after high-dose cytarabine may represent the reason explaining such a correlation, as previously reported. 13 Finally, in multivariate analysis we found that age is an independent factor affecting the outcome. Indeed, almost all deaths due to IA were observed in patients aged 60 years.
We wanted also to explore the role of AP, given in induction and consolidation, in preventing IA from occurring after consolidation. The AP during induction did not show a protective effect on the onset of IA during the consolidation phase of the chemotherapeutic programme. Such a lack of benefit may depend on the fact that the patients, immunosuppressed and frail, acquire the infection in the community, after hospital discharge. 26 Otherwise, posaconazole may control subclinical fungal infection or colonization at the time of prophylaxis, 27 reducing but not abrogating the risk of an overt infection at the time of subsequent episodes of immunosuppression.
The centres involved in this survey had different antifungal policies during the AML consolidation phase. Indeed, about half of them did not deliver AP, while the others used mould-active prophylaxis. Itraconazole was the most frequently dispensed drug, followed by posaconazole. The choice of some centres to use posaconazole was dictated by different reasons such as ongoing construction works nearby the hospital, absence of a laminar air flow room 28 or physicians' simple opinion that the patients were at high risk of developing IA. The results from our study show that in a large real-world setting, mould-active AP with itraconazole or posaconazole decreases the rate of IA after the consolidation course. The rate of our proven/probable breakthrough IA in patients treated with posaconazole was in line with the others' experience. 29 In our experience, AP appears to reduce the risk of IA after the consolidation course and strengthens the efficacy of antifungal therapy. Most of the patients who received AP responded well when the first-line antifungal therapy was instituted, and therefore we can assume that a broad-spectrum AP may decrease the rate of resistant pathogens, enhancing the action of the subsequent antifungal therapeutic regimen. The beneficial effect of prophylaxis was translated into number needed to treat, a metric of comparative efficacy that can be utilized to inform decisionmaking in clinical practice.
Our observation is in line with other studies previously reported 30, 31 and does not seem to confirm the increase of resistant Aspergillus species in breakthrough infections, although it remains difficult to draw any firm conclusion due to the low number of proven cases. Alternatively, AP may reduce the burden of fungal infections resulting in the occurrence of less severe forms of IA, which may better respond to antifungal treatment.
With the limitations of its retrospective nature, our study demonstrates that, in patients with AML, IA remains, even in consolidation, a rare but potentially life-threatening complication mainly among older patients treated with high-dose cytarabine. 
